Feng Wan

Prof. Feng Wan

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2010 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
FWFeng Wan
Feng Wan
SZSuojun Zhang
Suojun Zhang
RXRuifan Xie
Ruifan Xie
BGBaocheng Gao
Baocheng Gao
BCBenito Campos
Benito Campos
TLTing Lei
Ting Lei

1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
ZCZirong Chen
Zirong Chen
JWJunhong Wang
Junhong Wang
PPPeng Peng
Peng Peng
GLGuohao Liu
Guohao Liu
MDMinhai Dong
Minhai Dong
FWFeng Wan
Feng Wan
Rationale: Glioma stem cells (GSCs) have emerged as pivotal drivers of tumor malignancy, sustained by various microenvironmental factors, including immune molecules and hypoxia. In our previous study, we elucidated the significant role of transforming growth factor beta-induced protein (TGFBI), a protein secreted by M2-like tumor-associated macrophages, in promoting the malignant behavior of glioblastoma (GBM) under normoxic conditions. Building upon these findings, the objective of this study was to comprehensively explore the crucial role and underlying mechanisms of autocrine TGFBI in GSCs under hypoxic conditions.

10 October 2008 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
FWFeng Wan
Feng Wan
KSKai Shu
Kai Shu
TLTing Lei
Ting Lei
DXDelin Xue
Delin Xue

11 October 2013 in Oncology Letters
Verified
Journal Article
Open access
PDF file
SZSuojun Zhang
Suojun Zhang
RXRuifan Xie
Ruifan Xie
FWFeng Wan
Feng Wan
FYFei Ye
Fei Ye
DGDongsheng Guo
Dongsheng Guo
TLTing Lei
Ting Lei
Glioblastoma, the most common and lethal type of intracranial tumor, is characterized by extensive heterogeneity at the cellular and molecular levels. The discovery of glioma stem cells (GSCs) lends support to a new paradigm in tumor biology. In the present study, we aimed to clarify the validity of using U251 glioma cells as a source of GSC culture and critically evaluate the heterogeneous stem-like phenotypes of these cells when grown under various culture conditions. The findings suggested that U251 cells (U251-Adh, U251-SC-Sph and U251-SC-Adh) showed distinctive growth patterns and self-renewal capacity. The U251 glioma cell line is endowed with certain GSC phenotypes that may be moderately enriched in vitro when transferred into stem cell culture conditions, although this is not sustainable and reproducible in vivo. Notably, glioma cells are plastic in response to their environment. The reversible adaptive plasticity contributes to the GSC heterogeneity, which may lead to the heterogeneity of glioblastoma and the differing responses to current therapies. Therefore, an improved understanding of GSC heterogeneity is urgently required for designing more effective therapies against this highly malignant brain tumor.

19 October 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
PPPeng Peng
Peng Peng
ZCZirong Chen
Zirong Chen
XZXiaolin Zhang
Xiaolin Zhang
ZGZhongyin Guo
Zhongyin Guo
FDFangyong Dong
Fangyong Dong
FWFeng Wan
Feng Wan
Background Despite psychiatric traits were associated with intracranial aneurysms (IAs) in observational studies, their causal relationships remain largely undefined. We aimed to assess the causality between psychiatric traits and IAs.Methods We firstly collected the genome-wide association statistics of IAs (sample size, n = 79,429) and ten psychiatric traits from Europeans, including insomnia (n = 1,331,010), mood instability (n = 363,705), anxiety disorder (n = 83,566), major depressive disorder (MDD) (n = 480,359), subjective wellbeing (n = 388,538), attention deficit/hyperactivity disorder (ADHD) (n = 53,293), autism spectrum disorder (ASD) (n = 46,350), bipolar disorder (BIP) (n = 51,710), schizophrenia (SCZ) (n = 105,318), and neuroticism (n = 168,105). We then conducted a series of bi-directional two-sample Mendelian randomization (MR) analyses, of which the Robust Adjusted Profile Score (RAPS) was the primary method to estimate the causal effects between these psychiatric traits and IAs.Results We found that insomnia exhibited a significant risk effect on IAs with the odds ratio (OR) being 1.22 (95% CI: 1.11–1.34, p = 4.61 × 10–5) from the RAPS method. There was suggestive evidence for risk effect of mood instability on IAs (RAPS, OR = 4.16, 95% CI: 1.02–17.00, p = 0.047). However, no clear evidence of causal effects on IAs for the rest eight psychiatric traits (anxiety disorder, MDD, subjective wellbeing, ADHD, ASD, BIP, SCZ, and neuroticism) was identified. In the reverse MR analyses, no causal effects of IAs on psychiatric traits were found.Conclusions Our findings provide strong evidence for a causal risk effect of insomnia on IAs and suggestive evidence for mood instability as a causal risk effect on IAs. These results could inform the prevention and clinical intervention of IAs.

5 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ZCZirong Chen
Zirong Chen
PPPeng Peng
Peng Peng
XZXiaolin Zhang
Xiaolin Zhang
BMBarbara Mania-Farnell
Barbara Mania-Farnell
GXGuifa Xi
Guifa Xi
FWFeng Wan
Feng Wan
Diffuse intrinsic pontine gliomas (DIPGs) account for ~15% of pediatric brain tumors, which invariably present with poor survival regardless of treatment mode. Several seminal studies have revealed that 80% of DIPGs harbor H3K27M mutation coded by HIST1H3B, HIST1H3C and H3F3A genes. The H3K27M mutation has broad effects on gene expression and is considered a tumor driver. Determination of the effects of H3K27M on posttranslational histone modifications and gene regulations in DIPG is critical for identifying effective therapeutic targets. Advanced animal models play critical roles in translating these cutting-edge findings into clinical trial development. Here, we review current molecular research progress associated with DIPG. We also summarize DIPG animal models, highlighting novel genomic engineered mouse models (GEMMs) and innovative humanized DIPG mouse models. These models will pave the way towards personalized precision medicine for the treatment of DIPGs.